All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Bracco Imaging SpA. is buying prostate cancer imaging specialist Blue Earth Diagnostics Ltd. for $450 million, acquiring full rights to Axumin (F18-fluciclovine), a PET radiocontrast agent originally developed by Chicago-based GE Healthcare.
